Pulmatrix (PULM)
NASDAQ:PULM
Top Page
Pulmatrix
(NASDAQ:PULM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▼(-57.45% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by very weak fundamentals (near-zero TTM revenue, ongoing losses and cash burn, and a shrinking equity base) and a strong bearish technical trend (price well below key moving averages with negative MACD). Corporate events add some upside via a proposed merger and new financing, but the high dilution and recent deal termination keep overall risk elevated.
Positive Factors
Low Leverage
Pulmatrix’s zero reported debt is a durable financial advantage: it lowers fixed obligations and reduces bankruptcy risk, giving management flexibility to allocate scarce capital toward R&D, M&A integration, or milestone-driven development without near-term interest burdens that constrain many biotech peers.
Negative Factors
Minimal Revenue & Ongoing Losses
Persistently near-zero trailing revenue combined with multi-year net losses signals a structural inability to self-fund operations from product sales. Without commercial receipts, the firm remains dependent on external capital to advance trials, making long-term sustainability contingent on successful development or recurring financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Pulmatrix’s zero reported debt is a durable financial advantage: it lowers fixed obligations and reduces bankruptcy risk, giving management flexibility to allocate scarce capital toward R&D, M&A integration, or milestone-driven development without near-term interest burdens that constrain many biotech peers.
Read all positive factors
Pulmatrix (PULM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.60M
Dividend YieldN/A
Average Volume (3M)7.19K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue Growth-99.97%
EPS Growth35.59%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.57
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Pulmatrix Business Overview & Revenue Model
Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based o...
How the Company Makes Money
null...
Pulmatrix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
30
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 7.81M | 7.30M | 6.07M | 5.17M |
| Gross Profit | 0.00 | 640.00K | -8.22M | -12.17M | -10.21M |
| EBITDA | -5.16M | -7.04M | -14.61M | -18.79M | -16.42M |
| Net Income | -5.16M | -9.56M | -14.12M | -18.84M | -20.17M |
Balance Sheet | |||||
| Total Assets | 4.14M | 9.94M | 33.96M | 40.95M | 58.82M |
| Cash, Cash Equivalents and Short-Term Investments | 4.09M | 9.52M | 19.17M | 35.63M | 53.84M |
| Total Debt | 0.00 | 0.00 | 8.76M | 857.00K | 2.29M |
| Total Liabilities | 329.00K | 996.00K | 15.96M | 9.84M | 11.37M |
| Stockholders Equity | 3.81M | 8.95M | 18.00M | 31.11M | 47.45M |
Cash Flow | |||||
| Free Cash Flow | -5.43M | -11.11M | -16.66M | -19.44M | -19.87M |
| Operating Cash Flow | -5.43M | -10.72M | -15.98M | -19.36M | -19.73M |
| Investing Cash Flow | 0.00 | -398.00K | -676.00K | -86.00K | -144.00K |
| Financing Cash Flow | 0.00 | 0.00 | 53.00K | 1.23M | 43.48M |
Pulmatrix Technical Analysis
Negative
2.35
Price Trends
2.24
Negative
2.84
Negative
4.05
Negative
Market Momentum
-0.31
Positive
28.78
Positive
6.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PULM, the sentiment is Negative. The current price of 2.35 is above the 20-day moving average (MA) of 1.79, above the 50-day MA of 2.24, and below the 200-day MA of 4.05, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 28.78 is Positive, neither overbought nor oversold. The STOCH value of 6.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PULM.
Pulmatrix Risk Analysis
Pulmatrix disclosed 45 risk factors in its most recent earnings report. Pulmatrix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulmatrix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $15.26M | -4.54 | -59.29% | ― | -44.31% | -34.17% | |
46 Neutral | $76.00M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
43 Neutral | $4.60M | -1.58 | -79.47% | ― | -99.97% | 35.59% | |
43 Neutral | $12.01M | -1.16 | -89.92% | ― | ― | 53.19% | |
41 Neutral | $4.85M | -0.54 | -1292.87% | ― | ― | 18.47% | |
40 Underperform | $6.24M | -1.04 | -49.00% | ― | 47.17% | 26.84% |
* Healthcare Sector Average
PULM
Pulmatrix
1.26
-4.14
-76.67%
IBIO
Ibio
2.20
1.00
83.33%
LPCN
Lipocine
2.09
-0.98
-31.92%
IMRN
Immuron
0.80
-0.90
-52.94%
CMMB
Chemomab Therapeutics
1.67
-2.60
-60.89%
FBLG
FibroBiologics, Inc.
1.38
-16.42
-92.25%
Pulmatrix Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq
Positive
Mar 27, 2026
On March 26, 2026, Pulmatrix agreed to acquire Eos SENOLYTIX in an all-stock merger that will leave pre-merger Eos investors owning about 94% of the combined company, which will be renamed Eos SENOLYTIX, Inc. and is expected to continue trading on...
Business Operations and StrategyM&A Transactions
Pulmatrix Pursues New Reverse Merger After Cullgen Termination
Negative
Mar 2, 2026
On February 28, 2026, Cullgen notified Pulmatrix that it was terminating their previously agreed merger, which had been signed in November 2024 and amended in April 2025, after prolonged delays in securing approval from the China Securities Regula...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.